BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 21441466)

  • 21. Tissue microarray in a subset of South African patients with DLBCL.
    Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
    Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
    van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
    J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.
    Frauenfeld L; Castrejon-de-Anta N; Ramis-Zaldivar JE; Streich S; Salmerón-Villalobos J; Otto F; Mayer AK; Steinhilber J; Pinyol M; Mankel B; Ramsower C; Bonzheim I; Fend F; Rimsza LM; Salaverria I; Campo E; Balagué O; Quintanilla-Martinez L
    Blood Adv; 2022 Apr; 6(7):2361-2372. PubMed ID: 34654055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.
    Zhao S; Dong X; Shen W; Ye Z; Xiang R
    Cancer Med; 2016 May; 5(5):837-52. PubMed ID: 26869285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
    Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
    Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
    Ott G; Ziepert M; Klapper W; Horn H; Szczepanowski M; Bernd HW; Thorns C; Feller AC; Lenze D; Hummel M; Stein H; Müller-Hermelink HK; Frank M; Hansmann ML; Barth TF; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Loeffler M; Rosenwald A
    Blood; 2010 Dec; 116(23):4916-25. PubMed ID: 20736456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
    Bhattacharyya I; Chehal HK; Cohen DM; Al-Quran SZ
    Head Neck Pathol; 2010 Sep; 4(3):181-91. PubMed ID: 20533006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies.
    Coutinho R; Clear AJ; Owen A; Wilson A; Matthews J; Lee A; Alvarez R; Gomes da Silva M; Cabeçadas J; Calaminici M; Gribben JG
    Clin Cancer Res; 2013 Dec; 19(24):6686-95. PubMed ID: 24122791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary central nervous system lymphoma: Comprehension of cell-of-origin subtypes.
    Rao S; Epari S; Shet TM; Gujral S; Jain H; Bagal B; Senagar M; Shetty P; Moiyadi A; Goda JS; Gupta T
    Indian J Pathol Microbiol; 2023; 66(3):549-555. PubMed ID: 37530337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
    Ye ZY; Cao YB; Lin TY; Lin HL
    Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified.
    Cho I; Yoon N; Hyeon J; Sim J; Yoo HY; Kim SJ; Kim WS; Ko YH
    Appl Immunohistochem Mol Morphol; 2020; 28(10):731-740. PubMed ID: 32287077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab.
    Benesova K; Forsterova K; Votavova H; Campr V; Stritesky J; Velenska Z; Prochazka B; Pytlik R; Trneny M
    Neoplasma; 2013; 60(1):68-73. PubMed ID: 23067219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms.
    Read JA; Koff JL; Nastoupil LJ; Williams JN; Cohen JB; Flowers CR
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):460-467.e2. PubMed ID: 25052052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.
    Chang ST; Chen SW; Ho CH; Kuo CC; Sakata S; Takeuchi K; Chuang SS
    J Formos Med Assoc; 2016 Nov; 115(11):961-967. PubMed ID: 27773559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Cho MC; Chung Y; Jang S; Park CJ; Chi HS; Huh J; Suh C; Shim H
    Medicine (Baltimore); 2018 Nov; 97(45):e13046. PubMed ID: 30407302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.